Form 4: VolitionRx CEO Cameron Reynolds Acquires Shares in Registered Direct Offering

VolitionRx CEO Cameron John Reynolds purchased 181,818 shares of common stock at $0.55 per share in a registered direct offering.

Summary

• Cameron John Reynolds, the President and CEO of VolitionRx Ltd, acquired 181,818 shares of common stock on March 26, 2025.
• The shares were purchased at a price of $0.55 per share as part of a registered direct offering.
• Following the transaction, Reynolds directly owns 2,299,222 shares of VolitionRx Ltd.
• Reynolds also indirectly owns 1,007,718 shares through Concord International, Inc., where he is the majority shareholder and shares voting and dispositive control.
• Additionally, he indirectly owns 34,076 shares through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase indicates confidence, but it's a routine filing.

Positives

• The CEO's purchase of shares in a direct offering could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by the CEO is generally viewed positively.

Stakeholder Impact

• The CEO's purchase could positively influence shareholder sentiment.

Key Dates

Keywords

VolitionRx, VNRX, Cameron Reynolds, insider trading, registered direct offering, beneficial ownership, Form 4, SEC